Cargill's EpiCor postbiotic shows rapid immunomodulatory effects in new trial
A recent Cargill-funded study indicates a single 500mg dose of EpiCor postbiotic rapidly modulates immune markers within hours, potentially offering brands a fast-acting immune support claim.
London, United Kingdom — 06 August 2026
New research, funded by ingredient supplier Cargill, suggests that a single 500mg dose of their yeast-derived postbiotic, EpiCor, can rapidly influence immune activity within hours of consumption. The randomised, placebo-controlled crossover clinical trial, conducted in the US and Canada, involved 30 healthy adults and evaluated the immunomodulatory effects of the postbiotic. Researchers observed significant reductions in key inflammatory cytokines, including IFN-γ and IL-1ra after one hour, followed by decreases in IL-4, IL-7, and IL-8 at two hours post-ingestion, without broad immune suppression.
The study’s findings, published in Frontiers in Nutrition, indicate that EpiCor impacts immune cell behaviour by reducing the proportion of CD25-positive immune cells, suggesting activated immune cells are migrating from the bloodstream into tissues. This targeted modulation of immune responses, initiated at the gut mucosa, could trigger systemic effects. This research reinforces previous studies which demonstrated EpiCor's ability to enhance immune activity, increase mucosal immune protection, and reduce inflammatory responses.
Postbiotics, defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as a preparation of inanimate microorganisms and/or their components conferring a health benefit, are gaining traction for their direct interaction with intestinal and immune cells. This new evidence provides manufacturers with robust data to support 'acute' or 'rapid' immune support claims, moving beyond general immune health messaging.
What this means for United Kingdom
UK brand owners can capitalise on this data to formulate and market immune support products with rapid-acting benefits, differentiating from the saturated probiotic market. This allows for premium positioning and expands usage occasions beyond daily maintenance. Regulatory teams should prepare to substantiate 'fast-acting' immune claims to the FSA or MHRA, ensuring data from Frontiers in Nutrition is directly referenced. Procurement leads should assess the availability and lead times for EpiCor, anticipating increased demand as brands reformulate. Competitively, brands that are swift to market with well-substantiated rapid-action postbiotic products will gain first-mover advantage in a competitive functional foods and supplements sector.
The study's conclusion highlights the potential for EpiCor to act as an acute nutritional modulator of immune signalling, engaging gut-associated immune pathways. While the current study focused on immediate effects, the broader implication is to explore if these early changes contribute to the long-term health benefits previously associated with EpiCor, potentially broadening its application beyond acute immune support.
Many leading brands in this category are manufactured in partnership with Supplement Factory.